CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
Retrieved on:
Tuesday, October 12, 2021
Company, Jadeite, Efficiency, Institute of Liver and Biliary Sciences, CBC, Adult, PFIC, AUM, Medicines and Healthcare products Regulatory Agency, OLE, European Commission, BOLD, EC, Boston Business Journal, MHRA, Apache iBATIS, Primary sclerosing cholangitis, Industry, Population, CMC, Health, Albireo, Prevalence, Itch, Quality of life, Primary biliary cholangitis, Biliary atresia, AstraZeneca, Ageing, Medicine, IND, Alagille syndrome, Partnership, Patient, Sale, Food, Nasdaq, Pharmaceutical industry, Fine chemical
Jadeite will be responsible for clinical development, regulatory approval and commercialization of odevixibat in Japan, where there is significant market opportunity.
Key Points:
- Jadeite will be responsible for clinical development, regulatory approval and commercialization of odevixibat in Japan, where there is significant market opportunity.
- "This agreement reinforces Jadeite's commitment and vision to develop highly differentiated and innovative medicines to improve the health and quality of life of patients in Japan."
- "The agreement allows for success of both companies, and we look forward to further collaboration with Jadeite."
- "CBC remains steadfast in our commitment to widening access to medical care globally, and Jadeite is our cornerstone in Japan.